Latest Recommendations for Broad Molecular Testing in Advanced NSCLC
September 14th 2022During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Read More
Primary End Point of Improved DFS Not Met With Adjuvant Canakinumab in NSCLC
September 12th 2022Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.
Read More
MEDI5752 Plus Chemotherapy Produces Long DOR, But High Dose Comes With High Toxicity
September 11th 2022Chemotherapy added to 1500 mg of MEDI5752, a PD-1/CTLA-4 bispecific monoclonal antibody, led to a doubling in duration of response compared with pembrolizumab and chemotherapy in patients with treatment-naïve nonsquamous non–small cell lung cancer.
Read More
Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic Strategy
September 8th 2022In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.
Read More
SELECT Study of Vopratelimab With/Without Pimivalimab Misses Primary End Point in NSCLC
August 31st 2022Top-line data from the SELECT trial of vopratelimab plus pimivalimab vs pimivalimab alone missed its primary end point of mean tumor change but showed encouraging trends for secondary end points.
Read More
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2+ Metastatic NSCLC
August 12th 2022Accelerated approval has been granted to trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic non-small cell lung cancer based on positive results from DESTINY-Lung02.
Read More
Upfront Avelumab Shows Modest Survival Benefit Over Chemo in Advanced PD-L1+ NSCLC
August 9th 2022Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.
Read More
Pembrolizumab Plus Etoposide Continues to Show Survival Benefit in Untreated ES-SCLC
August 9th 2022Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.
Read More
New Strategies Needed for Patients With NSCLC Who Progress on Chemoimmunotherapy
August 8th 2022Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.
Read More
Neoadjuvant Chemoimmunotherapy Shows Significant Survival Benefit in Stage III NSCLC
August 8th 2022Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.
Read More